Started dose of regorafenib and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): A systematic review and meta-analysis.

Mikhail Fedyanin,Elizaveta Polyanskaya,Ilya Pokataev,Alexey Tryakin,Sergei Tjulandin

Started dose of regorafenib and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): A systematic review and meta-analysis.

2020

Mikhail Fedyanin
Elizaveta Polyanskaya
Ilya Pokataev
Alexey Tryakin
Sergei Tjulandin

131Background: Regorafenib is one of the standards of care in pts with chemorefractory mCRC. However, high toxicity is a common reason of treatment discontinuation, interruption and dose reduction....

Keywords:

Internal medicine
Regorafenib
Meta-analysis
Medicine
Colorectal cancer
Oncology
Pathology
Toxicity
in patient
dose reduction
Discontinuation
overall survival
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations